NCT01769885撤回不适用
A Pilot Clinical Trial of Neoadjuvant Tivozanib in Localized Renal Cell Carcinoma
适应症
干预措施
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 撤回
- 主要终点
- Feasibility of conducting a trial of tivozanib in terms of patients completing 2 courses of tivozanib
研究概览
简要总结
This clinical trial studies tivozanib before surgery in treating patients with localized kidney cancer. Tivozanib may stop the growth of tumor cells by blocking some of the growth factors needed for cell growth.
详细描述
PRIMARY OBJECTIVES:
I. To assess the feasibility of conducting a trial of tivozanib in the neoadjuvant setting of localized (completely resectable) renal cell cancer (RCC).
SECONDARY OBJECTIVES:
I. To evaluate the safety of tivozanib in the neoadjuvant setting. II. To compare the tissue before and after tivozanib for pharmacodynamic purposes (tumor infiltrating lymphocytes, myeloid derived suppressor cells, necrosis in the primary tumor after exposure to tivozanib).
III. To assess the overall response rate of tivozanib in primary tumors and correlate the radiographic changes, if any, to histo-pathological changes in the pathology specimen post-nephrectomy.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Biopsy proven non-metastatic clear cell RCC, as per radiographic studies is T2 - T3a based on the American Joint Committee on Cancer (AJCC) 6th edition criteria
- •Have an Eastern Cooperative Oncology Group (ECOG) performance status of =< 2
- •Hemoglobin >= 10 gm/dL
- •Absolute neutrophil count (ANC) >= 1.5 X 10^9/L
- •Platelets >= 100 X 10^9/L
- •Total bilirubin < 1.5 X upper limit of normal (ULN)
- •Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) < 2.5 X ULN
- •International normalization ratio (INR) < 1.5
- •Activated partial thromboplastin time (aPTT) < 1.2 X ULN
- •Serum creatinine < 1.5 mg/dL or if >= 1.5 mg/dL: calculated creatinine clearance (CrCL) > 30 mL/min based on Cockroft-Gault formula
- •Must have the ability to swallow and retain oral medication
- •Patients of childbearing potential must agree to use acceptable contraceptive methods (e.g., double barrier) during treatment
- •Patient or legal representative must understand the investigational nature of this study and sign an Independent Ethics Committee/Institutional Review Board approved written informed consent form prior to receiving any study related procedure
排除标准
- •Pregnant or nursing female patients
- •Unwilling or unable to follow protocol requirements
- •Any condition which in the Investigator's opinion deems the patient an unsuitable candidate to receive tivozanib (solitary kidney, multiple tumors in the same or contralateral kidney)
- •Not a candidate for surgery
- •Received an investigational agent within 30 days prior to enrollment
- •Non-clear cell or sarcomatoid histology
- •Patients with metastatic disease at presentation
- •Prior therapy with tyrosine kinase inhibitor for RCC
- •A second primary malignancy (except squamous and basal cell carcinoma of skin) in the past 3 years
- •Active or chronic infections
- •Significant cardiovascular disease, including:
- •Clinically symptomatic left ventricular failure
- •Uncontrolled hypertension: systolic blood pressure of > 150 mmHg or diastolic blood pressure of > 100 mmHg documented on 2 consecutive measurements taken at least 24 hours apart
- •Myocardial infarction, severe angina, or unstable angina within 6 months prior to administration of first dose of tivozanib
- •History of serious ventricular arrhythmia (i.e., ventricular tachycardia or ventricular fibrillation)
- •Cardiac arrhythmias requiring anti-arrhythmic medications (except for atrial fibrillation that is well controlled with anti-arrhythmic medication)
- •Coronary or peripheral artery bypass graft within 6 months of screening
- •History of coronary artery disease or peripheral arterial disease
- •History of stroke or carotid endarterectomy
- •Patients who are taking cytochrome P450 system (CYP)3A4 inducers are excluded; patients taking CYP3A4 inducers that can be safely replaced with another agent may be enrolled after a 5 day washout period
研究组 & 干预措施
Treatment (tivozanib and surgery)
Experimental
Patients receive tivozanib PO QD on days 1-21. Treatment repeats every 28 days for 2 courses in the absence of disease progression or unacceptable toxicity. 25 days after completion of tivozanib, patients undergo curative nephrectomy.
干预措施: tivozanib (Drug)
Treatment (tivozanib and surgery)
Experimental
Patients receive tivozanib PO QD on days 1-21. Treatment repeats every 28 days for 2 courses in the absence of disease progression or unacceptable toxicity. 25 days after completion of tivozanib, patients undergo curative nephrectomy.
干预措施: therapeutic conventional surgery (Procedure)
结局指标
主要结局
Feasibility of conducting a trial of tivozanib in terms of patients completing 2 courses of tivozanib
时间窗: Up to 30 days after surgery
次要结局
- Short-term efficacy defined as a composite of presence of partial response/stable disease/complete response assessed radiographically and correlated with the nephrectomy specimen per the Response Evaluation Criteria in Solid Tumors (RECIST) criteria(Up to 30 days after surgery)
- Incidence of adverse events evaluated using Common Terminology Criteria for Adverse Events (CTCAE) version 4.0(Up to 30 days after surgery)
研究者
相似试验
终止
1 期
A Study of Tivozanib in Combination With Durvalumab in Subjects With Advanced Hepatocellular CarcinomaHepatocellular CarcinomaNCT03970616AVEO Pharmaceuticals, Inc.27
已完成
2 期
A Study of Tivozanib (AV-951), an Oral VEGF Receptor Tyrosine Kinase Inhibitor, in the Treatment of Renal Cell CarcinomaCarcinoma, Renal CellNCT00502307AVEO Pharmaceuticals, Inc.272
进行中（未招募）
1 期
Testing the Combination of the Anti-cancer Drugs XL184 (Cabozantinib) and Nivolumab in Patients With Advanced Cancer and HIVAdvanced Differentiated Thyroid Gland CarcinomaAdvanced Head and Neck CarcinomaAdvanced Hepatocellular CarcinomaAdvanced Kaposi SarcomaAdvanced Lung Non-Small Cell CarcinomaAdvanced Lung Small Cell CarcinomaAdvanced Malignant Solid NeoplasmAdvanced Ovarian CarcinomaAdvanced Prostate CarcinomaAdvanced Renal Cell CarcinomaAdvanced Thyroid Gland Medullary CarcinomaAdvanced Triple-Negative Breast CarcinomaAdvanced Urothelial CarcinomaAnatomic Stage III Breast Cancer AJCC v8Anatomic Stage IV Breast Cancer AJCC v8Castration-Resistant Prostate CarcinomaClinical Stage III Cutaneous Melanoma AJCC v8Clinical Stage IV Cutaneous Melanoma AJCC v8HIV InfectionMetastatic Differentiated Thyroid Gland CarcinomaMetastatic Head and Neck CarcinomaMetastatic Hepatocellular CarcinomaMetastatic Kaposi SarcomaMetastatic Lung Non-Small Cell CarcinomaMetastatic Lung Small Cell CarcinomaMetastatic Malignant Solid NeoplasmMetastatic MelanomaMetastatic Ovarian CarcinomaMetastatic Prostate CarcinomaMetastatic Renal Cell CarcinomaMetastatic Thyroid Gland Medullary CarcinomaMetastatic Triple-Negative Breast CarcinomaMetastatic Urothelial CarcinomaRecurrent Differentiated Thyroid Gland CarcinomaRecurrent Head and Neck CarcinomaRecurrent Hepatocellular CarcinomaRecurrent Kaposi SarcomaRecurrent Lung Non-Small Cell CarcinomaRecurrent Lung Small Cell CarcinomaRecurrent Malignant Solid NeoplasmRecurrent MelanomaRecurrent Ovarian CarcinomaRecurrent Prostate CarcinomaRecurrent Renal Cell CarcinomaRecurrent Thyroid Gland Medullary CarcinomaRecurrent Triple-Negative Breast CarcinomaRecurrent Urothelial CarcinomaRefractory Differentiated Thyroid Gland CarcinomaStage III Differentiated Thyroid Gland Carcinoma AJCC v8Stage III Hepatocellular Carcinoma AJCC v8Stage III Lung Cancer AJCC v8Stage III Ovarian Cancer AJCC v8Stage III Prostate Cancer AJCC v8Stage III Renal Cell Cancer AJCC v8Stage III Thyroid Gland Medullary Carcinoma AJCC v8Stage IV Differentiated Thyroid Gland Carcinoma AJCC v8Stage IV Hepatocellular Carcinoma AJCC v8Stage IV Lung Cancer AJCC v8Stage IV Ovarian Cancer AJCC v8Stage IV Prostate Cancer AJCC v8Stage IV Renal Cell Cancer AJCC v8Stage IV Thyroid Gland Medullary Carcinoma AJCC v8Advanced MelanomaNCT04514484National Cancer Institute (NCI)8
招募中
2 期
Neoadjuvant Toripalimab in Combination with Gemcitabine and Cisplatin Therapy in Local Advanced Bladder Cancer SubjectsUrinary Bladder CancerNCT04861584Zhujiang Hospital41
撤回
1 期
A Phase I/II Study of Tivozanib and Erlotinib as Initial Treatment for Metastatic Non-small Cell Lung Cancer Assigned by VeriStrat® Serum Proteomic EvaluationStage IV DiseaseEGFR Unknown or Wild-typeNon-small Cell Lung CancerNCT01728181University of Utah